Lv1
70 积分 2025-04-17 加入
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
12小时前
已完结
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
1天前
已完结
Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients
1天前
已完结
Empowering PARP inhibition through rational combination: Mechanisms of PARP inhibitors and combinations with a focus on the treatment of metastatic castration-resistant prostate cancer
1天前
已完结
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase 1b/2 dose-escalation and dose-expansion study
6天前
已完结
Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer
7天前
已完结
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer
7天前
已完结
Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment
8天前
已完结
Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment
8天前
已完结
Analysis of status and countermeasures of cancer incidence and mortality in China
9天前
已完结
皖公网安备34019202002308
